Pancreatic adenocarcinoma third line systemic treatments: a retrospective cohort study
Abstract Background Chemotherapy for metastatic pancreatic adenocarcinoma (PDAC) primarily relies on FOLFIRINOX (LV5FU- irinotecan – Oxaliplatine) and Gemcitabine – Nab-Paclitaxel in the first-line setting. However, second-lines remain less well-defined and there is limited data regarding third-line...
Wedi'i Gadw mewn:
| Prif Awduron: | , , , , , , , , , , , , |
|---|---|
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
BMC
2024-02-01
|
| Cyfres: | BMC Cancer |
| Pynciau: | |
| Mynediad Ar-lein: | https://doi.org/10.1186/s12885-024-12016-z |
| Tagiau: |
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|